di , 24/01/2024

Biotech Showcase™ 2024 Concludes with 3,400 attendees, 350 Presenting Companies, 1,250+ Investors and 100+ Members of the Media

SAN FRANCISCO–(BUSINESS WIRE) Demy-Colton and EBD Group’s Biotech Showcase™, the premier investor conference for private and micro to mid-cap biotechnology companies, concluded its 16th year, bringing together over 3,400 attendees – including a record-breaking 1,285 investors and 110 members of the media

Mary Schaheen, President of Prevail Partners, said, “As an active investor in clinical-stage biotech (both public and private companies), this is a must-attend conference. Biotech Showcase™ is true to its name – great companies are highlighted.”

Tina Elder, Global Managing Director, EBD Group US, said, “Biotech Showcase™ has once again shown itself to be the premiere destination for innovators and partners to access a powerful network of industry decision-makers, media and top investors. Many thanks to all our investors, speakers, sponsors and other attendees for enabling these important conversations that help drive the industry’s funding, collaboration and therapeutic breakthroughs.”

This year’s Biotech Showcase™, which also encompasses Seed Showcase and DigiMed Showcase, explored the groundbreaking innovations set to define 2024. Discussions covered a broad range of topics, including the transition of focus from rare to chronic illnesses, strategies to combat neurodegenerative diseases, and insights into navigating the biotech funding landscape. 120 speakers shared their insights and perspectives on various industry fronts, including:

  • Maha Katabi, General Partner, Sofinnova Investments
  • Brent Vaughan, CEO, Cognito Therapeutics
  • Samarth Kulkarni, CEO, CRISPR
  • Paul Stoffels, CEO & Chairman, Galapagos
  • Daniel Kraft, Founder & Chair, NextMed Health
  • Seema Kumar, CEO, Cure
  • Ted Love, Chairman, Biotechnology Innovation Organization
  • Ashley Zehnder, Co-Founder & CEO, Fauna Bio
  • Paul Bresge, CEO, Ray Therapeutics
  • John McDonald, Corporate Vice President, Global Head of Business Development and M&A, Novo Nordisk
  • And members of the media, including Adam Bluestein (Fast Company), Allison DeAngelis (STAT News), Kyle LaHucik (Endpoints News), Ron Leuty (San Francisco Business Times), Alex Philippidis (GEN) and David Ewing Duncan.

Sara Jane Demy, Founder and CEO of Demy-Colton, said, “This has been another successful year for Biotech Showcase™, with an unmistakable sense of excitement and buzz about the industry’s prospects for the year ahead. It affirms that this is the place to be to network, break news, find out what’s happening, get a read on the mood around key issues, and meet with companies, investors and media.”

Biotech Showcase™ also featured 350 companies, including public and private innovators, who provided company presentations, while attendees networked via 6,500 partnering meetings, both in-person and virtual. Sessions from Biotech Showcase™, including company presentations, audio recordings of all panels and other content, are available for registered attendees on the partneringONE® platform. Those interested in accessing program content can log in with their registration information.

For more information, please visit www.biotechshowcase.com or follow us on Twitter @DemyColton and @EBDGroup.

About Demy-Colton

Demy-Colton is a leading life sciences and digital health events organization, at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Biotech CEO Summit Europe™, Biotech CEO Summit™ in La Jolla, and Demy-Colton Virtual Salons. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders, where investment, learning, and thoughtful conversations thrive. For more information, visit www.demy-colton.com.

About EBD Group

EBD Group’s overriding mission is to help collaborations get started across the life sciences value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life sciences markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today, our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, ChinaBio® Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life sciences executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. For more information, please visit www.ebdgroup.com.


Katie Morris
ENTENTE Network of Companies